
AMAG Pharmaceuticals’ Makena (hydroxyprogesterone caproate) has failed to meet its co-primary endpoints in a trial of patients with a history …

GlaxoSmithKline has initiated Phase III studies to evaluate the safety and efficacy of an investigational treatment for babies born prematurely. …

Merck has offered to pay $100 million to resolve thousands of legal claims brought against it for selling a birth …

